FDC
|
FDC Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 17.29 | 16.39 | 18.74 | 11.70 | 12.82 |
| CEPS(Rs) | 20.92 | 19.69 | 21.19 | 14.03 | 15.01 |
| DPS(Rs) | 5.00 | 5.00 | - | - | - |
| Book NAV/Share(Rs) | 152.64 | 140.11 | 128.81 | 119.47 | 115.92 |
| Tax Rate(%) | 24.87 | 25.31 | 23.01 | 24.82 | 25.30 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.49 | 14.93 | 16.93 | 13.57 | 16.12 |
| EBIT Margin(%) | 16.98 | 16.63 | 20.02 | 14.24 | 18.59 |
| Pre Tax Margin(%) | 16.76 | 16.42 | 19.82 | 14.02 | 18.39 |
| PAT Margin (%) | 12.59 | 12.26 | 15.26 | 10.54 | 13.74 |
| Cash Profit Margin (%) | 15.24 | 14.73 | 17.25 | 12.66 | 16.11 |
| Performance Ratios | |||||
| ROA(%) | 7.42 | 7.67 | 9.39 | 6.23 | 7.59 |
| ROE(%) | 11.81 | 12.19 | 14.96 | 9.84 | 11.71 |
| ROCE(%) | 15.93 | 16.52 | 19.62 | 13.27 | 15.78 |
| Asset Turnover(x) | 0.59 | 0.63 | 0.62 | 0.59 | 0.55 |
| Sales/Fixed Asset(x) | 1.75 | 2.01 | 2.04 | 1.91 | 1.70 |
| Working Capital/Sales(x) | 2.91 | 3.01 | 2.66 | 2.58 | 2.16 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.57 | 0.50 | 0.49 | 0.52 | 0.59 |
| Receivable days | 21.28 | 18.98 | 21.91 | 20.32 | 22.35 |
| Inventory Days | 59.64 | 64.09 | 65.48 | 62.83 | 60.27 |
| Payable days | 105.74 | 96.96 | 101.39 | 87.78 | 73.73 |
| Valuation Parameters | |||||
| PER(x) | 18.58 | 24.06 | 22.66 | 21.94 | 20.04 |
| PCE(x) | 15.35 | 20.03 | 20.04 | 18.29 | 17.11 |
| Price/Book(x) | 2.10 | 2.81 | 3.30 | 2.15 | 2.22 |
| Yield(%) | 1.56 | 1.27 | - | - | - |
| EV/Net Sales(x) | 2.39 | 3.02 | 3.54 | 2.37 | 2.82 |
| EV/Core EBITDA(x) | 11.27 | 15.33 | 15.64 | 14.07 | 13.06 |
| EV/EBIT(x) | 13.65 | 17.60 | 17.20 | 16.16 | 14.72 |
| EV/CE(x) | 2.08 | 2.79 | 3.28 | 2.13 | 2.19 |
| M Cap / Sales | 2.41 | 3.05 | 3.56 | 2.39 | 2.84 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.98 | 8.50 | 8.92 | 16.74 | 14.61 |
| Core EBITDA Growth(%) | 10.63 | -5.61 | 46.32 | -8.78 | -23.50 |
| EBIT Growth(%) | 4.94 | -9.63 | 52.83 | -10.46 | -25.23 |
| PAT Growth(%) | 5.49 | -12.55 | 57.39 | -10.33 | -28.23 |
| EPS Growth(%) | 5.49 | -12.55 | 60.21 | -8.77 | -28.19 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 2.58 | 2.31 | 2.22 | 1.98 | 2.05 |
| Quick Ratio(x) | 1.85 | 1.63 | 1.59 | 1.53 | 1.61 |
| Interest Cover(x) | 76.13 | 80.21 | 99.22 | 64.07 | 94.67 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of FDC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| FDC | ₹5,713.5 Cr | -1.2% | -1.2% | -24% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹447,716.0 Cr | -0.8% | -1.5% | 15.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹248,120.0 Cr | -3% | 8.3% | 52.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,038.0 Cr | -2.2% | -1.5% | 35% | Stock Analytics | |
| CIPLA | ₹110,858.0 Cr | -0.6% | -4.9% | -13% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,828.7 Cr | 0.2% | -3.9% | -11.8% | Stock Analytics | |
FDC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| FDC | -1.2% |
-1.2% |
-24% |
| SENSEX | -0.6% |
-4.4% |
-8.7% |
You may also like the below Video Courses